CIPROFLOXACIN AND DEXAMETHASONE

Post-LOE

ciprofloxacin hydrochloride and dexamethasone

Upsher Smith Labs

ANDAOTICSUSPENSION/DROPS

Approved

Jan 2026

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CIPROFLOXACIN AND DEXAMETHASONE (ciprofloxacin hydrochloride and dexamethasone) by Upsher Smith Labs is corticosteroid hormone receptor agonists [moa]. Approved for infections caused by susceptible isolates of the designated microorganisms in the specific condition listed below: acute otitis media (aom) in pediatric patients (age 6 months, older) with tympanostomy tubes due to staphylococcus aureus, streptococcus pneumoniae and 3 more indications. First approved in 2026.

Drug data last refreshed 3h ago

Mechanism of Action

Corticosteroid Hormone Receptor Agonists

Pharmacologic Class:

Corticosteroid

Indications (6)

infections caused by susceptible isolates of the designated microorganisms in the specific condition listed below: Acute Otitis Media (AOM) in pediatric patients (age 6 months older) with tympanostomy tubes due to Staphylococcus aureus

Worked on CIPROFLOXACIN AND DEXAMETHASONE at Upsher Smith Labs? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.